Barbro I. Eriksson

Barbro I. Eriksson

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.

Journal: ESMO open

Published: September 25, 2025

The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study.

The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study.

Journal: Journal of neuroendocrinology

Published: September 19, 2024

Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT.

Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 14, 2024

Learning from each other: Cross-cutting diagnostic development activities between magnetic and inertial confinement fusion (invited).

Learning from each other: Cross-cutting diagnostic development activities between magnetic and inertial confinement fusion (invited).

Journal: The Review of scientific instruments

Published: May 11, 2024

The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation.

The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation.

Journal: The Journal of pathology

Published: February 13, 2024

The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a Therapy Driven Route to High-Grade Transformation.

The Evolutionary History of Metastatic Pancreatic Neuroendocrine Tumours Reveals a Therapy Driven Route to High-Grade Transformation.

Journal: medRxiv : the preprint server for health sciences

Published: February 05, 2024

Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors.

Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors.

Journal: Endocrine connections

Published: January 25, 2022

Predictive Value of Ambulatory Objective Movement Measurement for Outcomes of Levodopa/Carbidopa Intestinal Gel Infusion.

Predictive Value of Ambulatory Objective Movement Measurement for Outcomes of Levodopa/Carbidopa Intestinal Gel Infusion.

Journal: Journal of personalized medicine

Published: November 24, 2021

New method for time alignment and time calibration of the TOFOR time-of-flight neutron spectrometer at JET.

New method for time alignment and time calibration of the TOFOR time-of-flight neutron spectrometer at JET.

Journal: The Review of scientific instruments

Published: April 06, 2021

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.

Journal: Neuroendocrinology

Published: September 19, 2019

High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors.

High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors.

Journal: Neuroendocrinology

Published: June 05, 2019

Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases.

Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases.

Journal: Acta neurologica Scandinavica

Published: March 21, 2019

Showing 1-12 of 46

Last Updated: 09/26/2026